Introduction
More than 5000 cardiac transplantations are performed each year for end-stage heart failure with a median survival of 13 years. 1 The main cause of death in patients 5 years after transplantation is graft failure due to cardiac allograft vasculopathy (CAV). 1 As a particular and accelerated type of coronary atherosclerosis, CAV develops early after transplantation in most patients and progresses steadily thereafter. A characteristic feature of CAV is the coexistence of focal, eccentric atherosclerotic plaques that affect epicardial coronary arteries and diffuse, concentric intimal thickening in intramyocardial arteries. 2, 3 An alloreactive immune response guided by T-cells induces the intimal hyperplasia by the accumulation of smooth muscle cells (SMCs). 4 Circulating vascular progenitor cells have been implicated in different types of atherosclerotic vascular diseases. 5 Whereas reduced numbers of CD34 + KDR + endothelial progenitor cells (EPCs) appear to predict cardiovascular events, the role of EPCs in the progression of atherosclerosis is controversial due to stagespecific contributions. 6 -9 CD14/CD105-bearing mononuclear cells, a putative subset of smooth muscle progenitor cells (SPCs), can acquire a-smooth muscle actin (a-SMA) and are increased in patients with coronary artery disease. 10 In acute coronary syndrome, however, SPCs are diminished, which has been implicated in plaque stability. 11 In animal studies, vascular incorporation of recipient-derived vascular progenitor cells clearly constitutes a significant number of endothelial cells and SMCs in transplanted vessels and contributes to allograft vasculopathy. 12, 13 Similar results have been described in humans. 14 -17 Studies that correlate circulating EPC levels with the presence of CAV, however, show conflicting results. 15, 18 Chemokines play a pivotal role in the vascular remodelling of transplanted vessels by directing the recruitment of vascular progenitor cells. 4, 19 Notably, the CXC chemokine stromal cell-derived factor (SDF)-1a/CXCL12 mediates the mobilization and local recruitment of SPCs in a mouse model of CAV, thereby contributing to neointima formation. 20 In addition, PDGF receptor-b (CD140b)-bearing SPCs are specifically mobilized into the circulation by CXCL12 after vascular injury in mice. 21 We, therefore, hypothesized that increased circulating CD34 + CD140b + SPCs and plasma CXCL12 levels might be associated with progressive CAV, whereas EPCs might be elevated in CAV-free patients.
Methods

Patient population
Between October 2007 and September 2008, a total of 207 adult heart transplant recipients were screened during routine outpatient visits at the Medical Centre of the University of Munich. The exclusion criteria were cardiac transplantation within the last 3 months, cancer, acute inflammatory disease, acute rejection, myocardial infarction within the last 2 weeks, and major peripheral artery disease. Finally, 187 patients were enrolled in this study. The Ethics Committee of the University of Munich approved the study protocol, and written informed consent was obtained from all participating subjects.
Cardiac allograft vasculopathy grading
Coronary angiograms were performed and independently evaluated by two cardiologists. Cardiac allograft vasculopathy was quantified by a scoring system, which determines the location and severity of vessel stenoses ( Table 1) . 22 On the basis of the sum of scores, each patient was categorized into one of the following groups: without CAV (score ¼ 0), mild CAV (score 1 -7), or severe CAV (score ≥8).
Intravascular ultrasound
Intravascular ultrasound (IVUS) data were obtained from the proximal part of the left anterior descending artery in 38 patients by continuous motorized pullback with an electronic sector scanner (Volcano, Eagle Eye catheter; 2.9F/20 MHz). 23 Two blinded investigators performed the quantitative analysis using dedicated software (Volcano pcVH Review Software), and the parameters were calculated as reported. 
CXCL12 enzyme-linked immunosorbent assay
Plasma CXCL12 was quantified using an enzyme-linked immunosorbent assay according to the manufacturer's protocol (RayBiotech, Inc.).
Statistical analysis
Continuous variables were summarized by means and standard deviations (+SD) or medians and interquartile ranges. These variables were compared by t-test, analysis of variance, or Mann-Whitney test. Categorical data were presented by frequencies and percentages, and compared with Fisher's exact test. Logistic regression models were used to analyse the joint relationship between patient characteristics ( Table 2 ) and CAV. For model building, all exploratory variables were studied univariately. CD34 + CD140b + SPC counts were categorized into two groups (≤0.05 and .0.05%). Thresholds were established using an ROC analysis. Factors that showed significant effects (P value ,0.05) in the univariate analysis were further studied in a multivariate model. To identify independent factors associated with the presence of CAV, a forward selection procedure with 0.05 as the significance level for entering a factor into the model was used. Finally, tests were assessed as significant, if the corresponding P value fell below the 5% margin. To compare SPCs, EPCs, CD34 + , KDR + , CD140b + cells, and CXCL12 levels, an analysis of variance and pair-wise post hoc comparisons were performed. Differences for patients with previous stent implantation or various immunosuppressive regimes were analysed by unpaired t-tests. A linear regression was used to calculate the relationship between CXCL12 levels and circulating cells. Repeatability was characterized by computing an intraclass correlation coefficient for each cell population. The overall significance level for all statistical tests was defined as 5%. As all statistical tests were conducted entirely in an explorative manner, no a-adjustment for multiple testing was carried out. Thus, P values of ≤0.05 could be interpreted as statistically significant results with respect to the study population. All analyses were performed using SAS w statistical software (V9.1.3, SAS Institute).\
Results
Patient characteristics
The angiographic CAV (score ≥1) was established in 44 were significantly increased compared with CAV-free patients as determined by IVUS. Cardiac allograft vasculopathy patients were slightly older and the time after transplantation was about 3 years longer ( Table 2) . Coronary stent implantation had been performed in 23 patients with CAV, who were therefore more often treated with anti-platelet drugs than unstented patients ( Table 2) . Of note, serum creatinine levels, BMI, and donor age were significantly higher in CAV patients compared with CAV-free patients ( Table 2) . Different immunosuppressant drug combinations were equally distributed in both groups. Sirolimus treatment was more frequent in patients without CAV, whereas cyclosporine (CsA) was more prevalent in CAV patients ( Table 2) .
Smooth muscle progenitor cell and endothelial progenitor cell counts in cardiac allograft vasculopathy
The flow cytometry analysis revealed that circulating CD34 + CD140b + cells were exclusively characterized by the expression of the SMC marker a-SMA, indicating an SMC-like phenotype ( Figure 1 ). CD34 + CD140b + SPCs were detectable in a significantly higher proportion of patients with CAV (80.9%) than in CAV-free patients (59.5%) (P , 0.0001, Table 3 ). The percentage of patients with circulating CD34 + KDR + cells was similar irrespective of the presence of CAV (P ¼ 0.5325, Table 3 ). Notably, the number of circulating SPCs was significantly increased in stented CAV patients compared with unstented CAV patients (0.15 + 0.13 versus 0.10 + 0.08; P ¼ 0.0464; Figure 2A ), implying that peripheral SPC counts are associated with clinically relevant CAV. In contrast, the number of EPCs did not differ between stented and unstented CAV patients (0.04 + 0.06 versus 0.05 + 0.08%; P ¼ 0.6268; Figure 2B ). In patients with moderate CAV, the CD34 + CD140b + cell count was two-fold higher than in patients without CAV (0.095 + 0.080 versus 0.048 + 0.073%; P , 0.0001; Figure 3A) . Compared with patients with moderate CAV, SPC numbers were further increased by 39% in patients with severe CAV (0.158 + 0.134%; P ¼ 0.0023; Figure 3A ). The level of SPCs correlated with the CAV sum score (r ¼ 0.3236; P , 0.0001) and the number of both distal (r ¼ 0.3831; P , 0.0001) and proximal stenoses (r ¼ 0.2111; P ¼ 0.0013). In contrast, CD34 + KDR + cell counts did not statistically differ between patients without CAV (0.049 + 0.067%) and with moderate (0.053 + 0.084%) or severe CAV (0.045 + 0.057%; Figure 3B ). The counts for cells with only CD34, KDR, or CD140b expression did not correlate with the degree of CAV ( Figure 3C ), implying that increased CD34 + CD140b + cells are specifically associated with CAV severity.
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Circulating CXCL12 levels
The CXCL12 levels in patients without CAV (103 + 33 pg/mL, n ¼ 79) were significantly lower than in patients with moderate (119 + 48 pg/mL, n ¼ 43, P , 0.05) or severe CAV (144 + 58 pg/mL, n ¼ 14, P , 0.01) (Figure 4) . Compared with moderate CAV, CXCL12 levels were further elevated in patients with severe CAV (P , 0.05; Figure 4 ). Furthermore, CXCL12 concentrations correlated with the CD34 + CD140b + cell counts (r ¼ 0.2967, P ¼ 0.0005) ( Figure 5A ) but not with the CD34 + KDR + cell counts (r ¼ 20.02804, P ¼ 0.7459) ( Figure 5B ). In addition, no statistically significant difference in plasma CXCL12 concentration was observed in patients treated with sirolimus, MMF, tacrolimus, or CsA (data not shown).
Functional effects of CXCL12 on CD34 1 CD140b 1 cells
Whereas CXCL12 expression was absent in CD34 + CD140b + cells ( Figure 6A -C ), CXCR4 immunostaining was clearly evident in both CD34 + CD140b + cells and leucocytes ( Figure 6D-F Figure 6E and F ). CXCL12 also supported the adhesion of CD34 + CD140b + cells under flow conditions on TNA-a-stimulated endothelial cells ( Figure 6G ).
CD34
1 CD140b 1 cell count is independently associated with cardiac allograft vasculopathy
In a multivariate logistic regression model, the factors associated with CAV were analysed ( Table 4) . Donor age, platelet count, and creatinine levels, but not the time after transplantation, recipient age, BMI, sirolimus, or CsA treatment, were identified to be associated independently with CAV in this model. Notably, peripheral CD34 + CD140b + cell counts were also independently associated with the presence of CAV and appeared to add significant information beyond that provided by the other factors.
Discussion
We analysed putative CD34 + CD140b + SPCs and CD34 + KDR + EPCs in the circulation of heart transplant recipients and found a positive correlation of the SPC, but not the EPC counts, and of the plasma CXCL12 concentration with the severity of CAV. These findings are compatible with the hypothesis that CXCL12-mediated SPC mobilization is involved in the development of CAV. CD34 is predominantly expressed in haematopoietic stem cells, and circulating CD34 + cells have previously been identified to comprise progenitors for endothelial cells and SMCs. 25 Mobilization of CD34 + cells after coronary stent implantation is associated with whereas increased EPC-colony-forming units were found in patients with an acute rejection episode. 31 Our results confirm these findings in a larger cohort of patients demonstrating that neither the presence nor the number of CD34 + KDR + EPCs was related to CAV.
Uraemia has been shown to decrease peripheral EPC levels, 32 which could at least partially explain the pathogenic role of impaired renal function in CAV development. Compared with EPCs and EPC-like cells, the characterization of circulating SPCs is less well established. It has been consistently shown that peripheral blood CD34
+ cells can differentiate into SMCs in vitro following the addition of PDGF-BB, 11, 25, 27 which binds to the b-chain of the PDGF receptor (CD140b). CD140b is preferentially expressed in SMCs but not in endothelial cells, 33 and it is essential for the recruitment of SMCs during embryonic blood vessel formation. 34 Moreover, CD140b-expressing mouse SPCs are selectively mobilized and recruited into the neointima by CXCL12 after vascular injury. 21 We, therefore, studied and severe CAV. The relatively modest correlation of the individual CAV sum score with the SPC count might be related to the limitations of the angiographic method to detect subtle variations in neointima formation. Although the SPC count was higher than the EPC level, circulating SPCs are still rare. However, through continuous intimal accumulation and proliferation over the years, even a small number of circulating SPCs might be able to enhance neointimal hyperplasia in transplanted vessels. CXCL12 regulates vascular repair through the mobilization and neointimal recruitment of SPCs in animal models. 19, 35 In a murine aortic transplantation model, CXCL12 is up-regulated in aortic allografts and contributes significantly to neointima formation by attracting SPCs. 20 Elevated intragraft CXCL12 expression has also been described in cardiac transplant patients after peritransplant ischaemic injury, which is associated with poorer survival and enhanced CAV. 17 In line with these results, we found that plasma CXCL12 concentrations rose with increasing CAV severity and correlated with peripheral CD34 + CD140b + SPC counts.
Medial SMC apoptosis after mechanical injury up-regulates CXCL12 expression and initiates the replacement by circulating SPCs. 21 In transplant arteriosclerosis, apoptosis of medial SMCs that is induced by the allogenic immune response, e.g. via CD8
+ T-cells, is responsible for the neointimal accumulation of host-derived SMCs. 36, 37 Although medial SMC apoptosis has not directly been shown to increase CXCL12 expression in CAV, this response might be a general mechanism in vascular repair and it may provide a link between the allogenic immune response and CXCL12-mediated SPC recruitment. 19 In summary, we provide the first evidence for an association of circulating SPCs and plasma CXCL12 levels with the presence of CAV, which suggests an important role of CXCL12-mediated mobilization of SPCs in the pathogenesis of allograft vasculopathy. Further studies are needed to explore whether inhibition of the CXCL12-CXCR4 axis might be a therapeutic approach for the prevention of CAV by reducing SPC accumulation. 
